Artelo’s first BIO-Europe company presentation spotlights ART26.12’s Phase 1 safety profile and dosing flexibility
Market Chameleon (Wed, 7-Oct 11:51 AM)
ARTL files obesity patent after mouse study showed ~40% weight loss with semaglutide combo
Market Chameleon (Thu, 24-Sep 11:35 AM)
